Invasive Candida infections are important causes of morbidity and mortality in immunocompromised
and hospitalised patients. This article provides the joint recommendations of the …

Background The broad‐spectrum triazole isavuconazole is used for the treatment of invasive
aspergillosis and mucormycosis. Data regarding human plasma concentrations in clinical …

Ciprofloxacin is highly active against bacteria that commonly cause bone infections. However,
the time-course of ciprofloxacin in bone has not been characterized using population …

Background The broad‐spectrum antifungal isavuconazole is administered to treat invasive
aspergillosis and mucormycosis. Objectives Isavuconazole plasma concentrations in …

The pharmacokinetics in patients with cystic fibrosis (CF) has long been thought to differ
considerably from that in healthy volunteers. For highly protein bound β-lactams, profound …

Background: Therapeutic drug monitoring (TDM) of beta-lactam antibiotics has become a
valuable tool to guide dosing in critically ill patients. The main goal of the study was to compare …

To the Editor, Among 796 clinical trials to treat COVID-19, chloroquine and
hydroxychloroquine account for a large fraction with 46 trials for chloroquine and 120 trials for …

Quinolone antibiotics present an attractive oral treatment option in patients with cystic fibrosis
(CF). Prior studies have reported comparable clearances and volumes of distribution in …

This is the eleventh chapter of the guideline “Calculated initial parenteral treatment of bacterial
infections in adults–update 2018” in the 2 nd updated version. The German guideline by …

Background and Objectives Remdesivir and hydroxychloroquine are or were among the
most promising therapeutic options to tackle the current SARS-CoV-2 pandemic. Besides the …